期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

多发性骨髓瘤预后分析系统ISS的临床意义

下载PDF
导出
摘要 目的探讨多发性骨髓瘤患者预后分析系统ISS的临床意义。方法采用ISS预后分期方法,对49例MM患者的生存时间进行回顾性分析。结果Ⅰ期、Ⅱ期、Ⅲ期的中位生存时间分别是62月、42月3、6月。Ⅰ期和Ⅱ期、Ⅲ期生存时间有统计学意义(P<0.05),而Ⅱ期和Ⅲ期生存时间无统计学意义。结论ISS预后分期系统能较好地预测MM的预后。
作者 王晓刚 孙酬经 黄强 杨天新
机构地区 浙江省人民医院
出处 《浙江实用医学》 2005年第6期390-391,共2页 Zhejiang Practical Medicine
关键词 多发性骨髓瘤 预后平分 回顾性分析
分类号 R733.3 [医药卫生—肿瘤] R743.34 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献6

  • 1Durie BGM, Salmon SE. A clinical staging system for multiple myeloma.Correlation of measured myeloma cell mass with presenting clinical features,response to treatment and survival. Cancer, 1975,36:842
  • 2Greipp P R, San. Miguel G F, Durif B G. A new international staging system (ISS) for multiple myeloma(MM) from international Myeloma Working Group. J. Blood,2003,102(11 ): 118
  • 3Byar D P. Identification of prognostic factors [A]. Buyse M E, Seaquet M J, Sylveter R S. Cancer Clinical trials. Methods and practice. England:Oxford University press. 1984,423
  • 4Cuzick J, De Stavola BL, Cooper EH, et al. Long - term prognostic value of serum β2 microglobulin in myelomatosis. Br J Heamato 1990,175:506
  • 5Greipp P R, Jesus San Miguel, Brian G. M. et al. International Staging System for multiple myeloma. J Clin Oncol.2005,23(15):3412
  • 6张骏,巫刚,邓宏宇,李双庆.多发性骨髓瘤预后指标与Durie-Salmon分期和ISS分期的相关性分析[J].临床荟萃,2005,20(2):78-79. 被引量：5

二级参考文献11

  • 1CARBONE P, KELLERHOUSE L, GEHAN E. Plasmacytic myeloma: a study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients[J]. A J M, 1967, 42(6): 937-948.
  • 2COSTA G, ENGLE R L, SCHILLING A, a al. Melphalan and prednisone: an effective combination for the treatment of multiple myeloma[J]. AJM, 1973,54(4): 589-599.
  • 3DURIE B G, SALMON S. A clinical staging system of multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival[J]. Cancer, 1975, 36(3):842-854.
  • 4MERLINI G, WALDENSTROM I, JAYAKARS. A new improved clinical staging system for multiple myeloma based onthe analysis of 123 treated patients[J].Blood, 1980, 55(6):1011-1019.
  • 5GREIPP P R, LUST J A, O'FALLON W M. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein inmultiple myeloma[J]. Blood, 1993, 82(11) : 3507-3508.
  • 6SAN MIGUEL J F, GARCIA-SANZ R, GONZALEZ M. A new staging system for multiple myeloma based on the number of S-phase plasma cells[J]. Blood, 1995, 85(2) : 448-455.
  • 7JACOBSON J L, HUSSEIN M A, BARLOGIE B. A new staging system for multiple myeloma patients based on the Southwest Oneology Group (SWOG) experience[J]. Br J Haematol, 2003, 122(3): 441-450.
  • 8GREIPP P R, SAN MIGUEL G F, DURIE B G. A new international staging system(ISS) for multiple myeloma(MM)from the international myeloma working group[J]. Blood,2003, 102(11): 118.
  • 99th International Workshop on Multiple Myeloma[J/OL]. from http://www.medseape.com/viewar tiele/458148 -- 2.Medseape hematology-oneologyhome,2003,6(2)/2003-07-31.
  • 10WEBER D M, WANG M, DELASALLE K. Confirmation of prognostic value of model using B2-Microglobulin (B2M) and albumin for multiple myeloma ( MM ) proposed by the International Myeloma Working Group (IMWG) with similar results using B2M alone[J]. Blood, 2003, 102(11):937.

共引文献4

浙江实用医学
2005年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部